Globus Medical, Inc. (GMED)
NYSE: GMED · Real-Time Price · USD
72.90
-0.17 (-0.23%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Globus Medical Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Globus Medical stock have an average target of 96.91, with a low estimate of 80 and a high estimate of 115. The average target predicts an increase of 32.94% from the current stock price of 72.90.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Globus Medical stock from 13 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 5 | 4 | 4 | 4 |
| Buy | 4 | 5 | 5 | 5 | 5 | 5 |
| Hold | 3 | 2 | 3 | 4 | 4 | 4 |
| Sell | 1 | 1 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 13 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Hold Maintains $82 → $80 | Hold | Maintains | $82 → $80 | +9.74% | Apr 11, 2025 |
| Truist Securities | Truist Securities | Hold Maintains $90 → $82 | Hold | Maintains | $90 → $82 | +12.48% | Mar 18, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 18, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Feb 24, 2025 |
| Barclays | Barclays | Buy Maintains $100 → $103 | Buy | Maintains | $100 → $103 | +41.29% | Feb 24, 2025 |
Financial Forecast
Revenue This Year
2.75B
from 2.52B
Increased by 9.12%
Revenue Next Year
2.94B
from 2.75B
Increased by 6.91%
EPS This Year
3.51
from 0.75
Increased by 367.80%
EPS Next Year
4.01
from 3.51
Increased by 14.29%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.0B | 3.3B | 3.5B | ||
| Avg | 2.7B | 2.9B | 3.2B | ||
| Low | 2.6B | 2.8B | 3.0B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 20.5% | 19.4% | 17.6% | ||
| Avg | 9.1% | 6.9% | 7.3% | ||
| Low | 4.0% | 1.0% | 0.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.67 | 4.50 | 4.99 | ||
| Avg | 3.51 | 4.01 | 4.54 | ||
| Low | 3.28 | 3.61 | 4.06 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 389.7% | 28.4% | 24.4% | ||
| Avg | 367.8% | 14.3% | 13.1% | ||
| Low | 337.7% | 2.8% | 1.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.